Omalizumab

Omalizumab is a recombinant DNA-derived humanized monoclonal antibody approved for use in patients with moderate-to-severe or severe allergic asthma, which cannot be controlled even with high doses of corticosteroids. It selectively binds to human immunoglobulin E (IgE) antibody. IgE is commonly involved with allergies when present in high amounts in the body. If your asthma is poorly controlled (e.g., if you are using rescue inhalers twice a week or more, have night-time symptoms, or experience limitation in activities), consider requesting a consultation to address the underlying allergic triggers, optimize anti-inflammatory regimen and determine your candidature for Omalizumab. This medication can reduce or eliminate your dependence on steroids for asthma control within a few months (individual results may vary).